TY - JOUR
T1 - Crohn's disease
T2 - beyond antagonists of tumour necrosis factor
AU - Peyrin-Biroulet, Laurent
AU - Desreumaux, Pierre
AU - Sandborn, William J.
AU - Colombel, Jean Frédéric
N1 - Funding Information:
LP-B has received consulting fees from Abbott Laboratoires and UCB Pharma; lecture fees from speaking at continuing medical education events from Centocor; and grant support from AstraZeneca and UCB Pharma. PD has received consultancy fees from or has been on paid advisory boards for Biofortis, Danisco France SAS, Danone France, Ferring, Giuliani SpA, Roquette, UCB Pharma, and Txcell; received lecture fees from speaking at continuing medical education events from Procter and Gamble, Ferring, Schering Plough, Shire Pharmaceuticals, UCB Pharma; and received grant support AstraZeneca, Danisco France SAS, Danone France, Ferring, Giuliani SpA, Lesaffre, Ocera Therapeutics, Roquette, Sanofi-Synthelabo, UCB Pharma, and Yoplait. WJS has received consultancy fees from or has been on paid advisory boards for Abbott Laboratories, ActoGeniX NV, AGI Therapeutics, Alba Therapeutics, Alizyme, Alza, AstraZeneca, Avidia, Berlex Pharmaceuticals, BioBalance, Boehringer-Ingelheim, Bristol Meyers Squibb, Celegene, Centocor, Cerimon Pharmaceutical, Chemocentryx, CombinatoRx, CoMentis, Corautus Genetics, Cosmo Technologies, Effective Pharmaceuticals, Eisai Medical Research, Elan Pharmaceuticals, Enzo Therapeutics, Eurand, FlexPharm, Genencor International, Genentech, GlaxoSmithKline, H3 Pharma (name changed to Debiopharm SA in 2005), Hoffman LaRoche, Hutchison Medipharma, Inflabloc Pharmaceuticals (previously named Pharmadigm), Inotek Pharmaceutical, ISIS Pharmaceuticals, Jacobus Pharmaceutical Company, Johnson & Johnson Pharmaceutical Research & Development, LigoCyte Pharmaceuticals, McNeil Consumer and Specialty Pharmaceuticals, Medarex, Millenium Pharmaceuticals, Nisshin Kyorin Pharmaceutical Co, Novartis, NPS Pharmaceuticals, Ocera Therapeutics, Ono Pharma USA, Otsuka American Pharmaceuticals, PDL Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, Renovis, Salix Pharmaceuticals, Schering Plough, Serono, Shire Pharmaceuticals, Synta Pharmaceuticals, Targacept, Teva Pharmaceuticals, Therakos, UCB Pharma, and ViaCell; lecture fees from speaking at continuing medical education events from Abbott Laboratories, Axcan Pharmaceuticals, AstraZeneca, Centocor, Elan Pharmaceuticals Falk Pharma, Otsuka American Pharmaceuticals, PDL Biopharma, Procter and Gamble, Prometheus Laboratories, Salix Pharmaceuticals, Schering Plough, Shire Pharmaceuticals, and UCB Pharma; and grant support from Abbott Laboratories, Bristol Meyers Squibb, Centocor, Chemocentryx, Elan Pharmaceuticals, Otsuka American Pharmaceuticals, PDL Biopharma, Procter and Gamble, Shire Pharmaceuticals, and UCB Pharma. J-FC has received consultancy fees from or has been on paid advisory boards for Abbott Laboratories, ActoGeniX NV, AstraZeneca, Berlex, Boehringer-Ingelheim, Bristol Meyers Squibb, Centocor, Cosmo Technologies, Danone France, Elan Pharmaceuticals, Genentech, GlaxoSmithKline, Millenium Pharmaceuticals, Ocera Therapeutics, Otsuka American Pharmaceuticals, PDL Biopharma Schering Plough, Shire Pharmaceuticals, Synta Pharmaceutical, Teva Pharmaceuticals, Therakos, and UCB Pharma; lecture fees from speaking at continuing medical education events supported with unrestricted educational grants from Abbott Laboratories, AstraZeneca, Centocor, Elan Pharmaceuticals, Falk Pharma, Otsuka American Pharmaceuticals, PDL Biopharma, Schering Plough, Shire Pharmaceuticals, UCB Pharma, and Ferring; and grant support from AstraZeneca and Ferring.
PY - 2008
Y1 - 2008
N2 - In the past few years, antagonists of tumour necrosis factor have resulted in unforetold therapeutic benefits in Crohn's disease, but the magnitude and duration of responses are variable. New agents are therefore needed. Their development has benefited from advances in the understanding of the pathophysiology of this disease. Uncontrolled activation of the acquired immune system has an important role, and lymphocytes, cytokines, and adhesion molecules are broadly targeted for therapeutic intervention. With increasing evidence of an implication of the innate immune system and the intestinal epithelium, the therapeutic paradigm is also shifting from mere immunosuppression to the reinforcement of the intestinal barrier. We review mechanisms of actions of new drugs and the efficacy and adverse events from data from clinical trials. We discuss future directions, including new strategies with optimum endpoints.
AB - In the past few years, antagonists of tumour necrosis factor have resulted in unforetold therapeutic benefits in Crohn's disease, but the magnitude and duration of responses are variable. New agents are therefore needed. Their development has benefited from advances in the understanding of the pathophysiology of this disease. Uncontrolled activation of the acquired immune system has an important role, and lymphocytes, cytokines, and adhesion molecules are broadly targeted for therapeutic intervention. With increasing evidence of an implication of the innate immune system and the intestinal epithelium, the therapeutic paradigm is also shifting from mere immunosuppression to the reinforcement of the intestinal barrier. We review mechanisms of actions of new drugs and the efficacy and adverse events from data from clinical trials. We discuss future directions, including new strategies with optimum endpoints.
UR - http://www.scopus.com/inward/record.url?scp=46149125761&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(08)60995-2
DO - 10.1016/S0140-6736(08)60995-2
M3 - Review article
C2 - 18603161
AN - SCOPUS:46149125761
SN - 0140-6736
VL - 372
SP - 67
EP - 81
JO - The Lancet
JF - The Lancet
IS - 9632
ER -